Abstract 1069
Background
Alectinib is a CNS penetrant and highly selective ALK inhibitor. The Japanese Risk Management Plan based on the phase I/II studies highlighted interstitial lung disease (ILD), liver function disorder, decreased neutrophil cell and white blood cell counts as identified risk in Japanese patients (pts). To investigate the safety and effectiveness of alectinib, including adverse drug reactions (ADR) of particular concern in the real world setting, a large scale surveillance funded by Chugai Pharmaceuticals has been implemented. This study is registered with the UMIN, number UMIN000014989.
Methods
From Sep 2014 to June 2015 all pts with ALK-positive recurrent/advanced NSCLC treated with alectinib, were enrolled in the study. The observation period was 18 months, ADR were collected. Overall survival (OS) was also assessed.
Results
By Jun 2015, a total of 1251 pts were registered. We analysed 1221 pts as the safety population. Baseline characteristics included: female (54% of population), median age (62 years), ECOG PS 3-4 (n = 89) (7%), pts who received first line (18%), second line (32%) or third line or more (50%) treatments, pts who received crizotinib (63%), brain metastases (41%). The overall incidence of ADRs was 53.6% (mostly grade 1/2), the most common were laboratory tests abnormality (27.7%). ILD events were reported in 47 pts (3.8% of population), including grade 3 events in 8 pts and grade 4 events in 1 pt, in which the rate of recovery or improvement was 92%. Events of liver function disorder were reported in 242 pts (19.8%), including grade 3 events in 24 pts, and events of neutrophil cell and white blood cell decrease were reported in 93 pts (7.6%), including grade 3 events in 12 pts and grade 4 events in 2 pts, in which the rates of recovery or improvement were 83% and 93%, respectively. Median OS was not reached. Overall survival rate at 12 months and 18 months were 82.4% and 76.2%, respectively.
Conclusions
These final data from this study in Japanese ALK-positive NSCLC pts provide an acceptable safety and effectiveness profile in the real-world setting. Alectinib was primarily one of the effective therapies for the treatment of ALK-positive NSCLC.
Clinical trial identification
Legal entity responsible for the study
Chugai Pharmaceutical CO., LTD.
Funding
Chugai Pharmaceutical CO., LTD.
Editorial Acknowledgement
Disclosure
Y. Ohe: Consuting or advisory role, honoraria: Chugai Pharm Co., Ltd.; Research funding to institution: Chugai Pharm Co., Ltd. N. Yamamoto: Consuting or advisory role, speakers' bureau, honoraria: Chugai Pharm Co., Ltd. Research funding to instution: Chugai Pharm Co., Ltd. A. Gemma, M. Kusumoto, N. Masuda: Consuting or advisory role: Chugai Pharm CO., LTD. I. Yamada, T. Ishii: Employment: Chugai Pharm Co., Ltd.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract